This study is a single-centered, double-blind, two-arm randomized study to determine if oral glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving Therapy.
Subject have been diagnosed with Stage I or II invasive breast cancer Subject will undergo Accelerated Partial Breast Irradiation (APBI) as part of Breast Conserving Therapy (BCT) Subject is eligible for APBI based on American Society of Therapeutic Radiation Oncology (ASTRO) criteria Subject is 18 years of age or older Subject is female
Exclusion Criteria:
History of uncontrolled, clinically significant lung, heart, endocrine, liver, or renal disease Subject has been diagnosed with any other cancer Subject has a known hypersensitivity reaction to the following: oral glutamine (GLN), glutamate, monosodium glutamate (MSG) (i.e., Chinese restaurant syndrome) Subject has history of collagen vascular disease Subject has been diagnosed with Diabetes mellitus I or II Subject has had any prior breast radiation Subject is pregnant or breastfeeding
